New CDMO contract announcements and client pipeline visibility, particularly multi-year supply agreements with biotech/pharma clients
Facility capacity utilization rates and manufacturing efficiency metrics (batch success rates, turnaround times)
HA pricing trends and competitive dynamics with Asian suppliers (particularly Chinese fermentation producers)
Regulatory inspection outcomes and FDA compliance status for the Chaska facility
low-to-moderate - Pharmaceutical manufacturing demand is relatively recession-resistant as drug development and production continue through economic cycles. However, biotech funding conditions affect client pipeline, and elective medical procedures (orthopedic injections, aesthetic treatments using HA) show modest sensitivity to consumer discretionary spending. The company's negative margins create vulnerability to prolonged downturns that could constrain client capital allocation.
Rising interest rates negatively impact Lifecore through multiple channels: (1) higher financing costs on the company's substantial debt load (Debt/Equity of 3.74), pressuring already-negative cash flow; (2) reduced biotech/pharma client funding as venture capital and IPO markets tighten, potentially delaying CDMO projects; (3) lower valuation multiples for unprofitable growth companies. The 2-year Treasury yield directly affects refinancing risk and working capital costs.
CDMO commoditization risk as manufacturing capacity expands globally, particularly in lower-cost geographies (India, China), compressing pricing power for standard fill-finish services
HA market pricing pressure from Asian fermentation producers with 30-50% cost advantages, threatening margin sustainability in the commodity HA segment
Regulatory risk from FDA inspection findings or quality system deficiencies that could halt production or limit new client onboarding
value/turnaround - The stock appeals to distressed/special situations investors betting on operational turnaround, capacity utilization improvement, and margin expansion from current depressed levels. Small-cap healthcare specialists may see CDMO consolidation potential or niche positioning value. Not suitable for income investors (no dividend) or risk-averse growth investors given negative profitability and execution risk.
Trend
-18.0% vs SMA 50 · -37.1% vs SMA 200
Momentum
Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $127.8M $126.1M–$129.6M | — | -$1.33 | — | ±8% | Low2 |
FY2026(current) | $75.1M $73.1M–$77.6M | ▼ -41.2% | -$0.48 | — | ±5% | Moderate3 |
FY2027 | $122.2M $119.5M–$124.3M | ▲ +62.6% | -$1.04 | — | ±3% | Moderate4 |
INSTITUTIONAL OWNERSHIP
LFCR News
About
landec corporation (nasdaq:lndc) is a leading innovator of diversified health and wellness solutions within the packaged food and biomaterial markets. apio, landec's food business, is the leader in branded, packaged fresh vegetables in north america, utilizing its proprietary breatheway® packaging technology to naturally extend the shelf life of fresh produce. apio combines this technology with the capabilities of a large national fresh produce supplier to offer healthy fresh vegetable products under the eat smart® brand to consumers through club and retail grocery stores. lifecore biomedical, landec's biomaterial business, is a fully integrated contract development and manufacturing organization (cdmo) that offers expertise and capabilities in fermentation, specialty formulation, aseptic filling and final packaging for fda regulated medical devices and drugs to customers for applications in a wide array of markets including ophthalmic, orthopedic and oncology. for more information abo
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
LFCR◀ | $4.40 | -3.30% | $165M | — | +47.2% | -3004.4% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.01% | — | 50.3 | +341856.6% | -3931.1% | 1500 |